A phase I, randomized, single-dose pharmacokinetic study comparing sb8 (bevacizumab biosimilar) with reference bevacizumab in healthy volunteers

Shin, D; Lee, YJ; Choi, J; Lee, D; Park, M; Petkova, M

Shin, D (corresponding author), Samsung Bioepis Co Ltd, Med Affairs, Incheon, South Korea.

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2020; 86 (4): 567

Abstract

Purpose To compare pharmacokinetics, safety, tolerability, and immunogenicity between SB8, a bevacizumab biosimilar, and the European Union (EU) and U......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索